East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2019 to Jul 2024
Fast Growing Mid-Tier Pharmaceutical Awards $2 Million Study to
eResearchTechnology for Cardiac Safety Monitoring and Information Distribution
Services
Thorough Phase I ECG Study To Be Conducted Over 90-Day Period eRT Leveraging
Significant Experience with Later Phase Development of Compound
PHILADELPHIA, June 16 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc.
(eRT), (NASDAQ:ERES), a leading provider of centralized electrocardiographic
(ECG) collection and interpretation services, announced today that it has
received an agreement for more than $2 million in cardiac safety monitoring and
services from a fast growing mid-tier pharmaceutical for one of its drug
candidates in clinical development.
The agreement covers an extensive Phase I study for which eRT is providing
comprehensive support including the provision, training and ongoing assistance
required for effective use of digital 12-lead Holter equipment designed to
facilitate 24-hour digital recording of cardiac safety data that is
subsequently provided to eRT for analysis. eRT will perform digital
collection, measurement, interpretation, review, and distribution of cardiac
safety data through its EXPeRT(R) workflow enabled data handling technology,
the first solution in production that was designed explicitly to meet emerging
international regulatory guidance and technical standards. The study is
targeted for completion over a 90-day period.
"eRT is delighted to have been selected for this demanding study, which
provides an opportunity to leverage our experience gained in providing cardiac
safety services for later phase, multi-center studies for this novel pain
therapy," said Scott Grisanti, senior vice president of business development
and chief marketing officer at eRT. "This award illustrates the trend toward
drug developers working with a core laboratory, such as eRT, across all phases
of development to ensure consistency. eRT's investments in scientific and
operational resources, technology, and partnerships combine to address the
increasingly sophisticated requirements of sponsors striving to achieve Best
Practices in cardiac safety for new drug development."
Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/) is a
provider of technology and services to the pharmaceutical, biotechnology and
medical device industries on a global basis. The company is a market leader in
providing centralized core-diagnostic electrocardiographic (ECG) technology and
services to evaluate cardiac safety in clinical development. The company is
also a leader in providing technology and services to streamline the clinical
trials process by enabling its customers to automate the collection, analysis,
and distribution of clinical data in all phases of clinical development.
Statements included in this release may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Such statements involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the company's ability to
obtain new contracts and accurately estimate net revenues due to variability in
size, scope and duration of projects, and internal issues in the sponsoring
client. The sponsor may cancel this agreement at its sole discretion. As a
result, actual results may differ materially from any financial outlooks stated
herein. Further information on potential factors that could affect the
company's financial results can be found in the company's Reports on Forms 10-K
and 10-Q filed with the Securities and Exchange Commission.
DATASOURCE: eResearchTechnology, Inc.
CONTACT: Joan Sterlacci of eResearchTechnology, Inc., +1-908-203-6473,
or Matt Hayden of Hayden Communications, +1-858-456-4533, for
eResearchTechnology
Web site: http://www.ert.com/